Want to see SE:SANION full AI Analyst Report?
Saniona AB (SANION) Price & Analysis
SANION Stock Chart & Stats
- Day’s Range
- SEK 11.03 - SEK 11.55
- 52-Week Range
- SEK 8.53 - SEK 28.30
- Previous Close
- SEK 11.45
- Volume
- 166.26K
- Average Volume (3M)
- 441.00K
- Market Cap
- SEK 1.54B
- Enterprise Value
- SEK 1.32B
- Total Cash (Recent Filing)
- SEK 486.31M
- Total Debt (Recent Filing)
- SEK 0
- Price to Earnings (P/E)
- 8.3
- Beta
- 0.39
- Next Earnings
- Nov 26, 2026
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Profitability
The sharp improvement from heavy losses in 2021–2023 to strong 2025 and TTM profitability indicates meaningful earnings power today. If supported by ongoing business activity, these margins can fund development, strengthen resilience, and reduce reliance on external capital.
Debt-Free Balance Sheet
A debt-free balance sheet with substantial equity provides financial flexibility for a development-stage biotechnology company. It reduces interest and refinancing burdens, improves the ability to withstand operating volatility, and leaves more capacity to finance proprietary programs or partnerships.
Positive Cash Generation
Positive operating and free cash flow across the latest reported periods is an important sign that current operations are generating funding rather than consuming it. Sustained cash generation could support pipeline advancement and reduce dependence on equity issuance or other financing.
Bears Say
Revenue Volatility
The severe latest-TTM revenue decline after earlier surges makes the current earnings base difficult to forecast. Such volatility can reflect uneven licensing or milestone timing and may limit confidence that present profitability and cash generation will persist through the next several quarters.
Weak Earnings Growth
Negative EPS growth indicates that per-share earnings are weakening despite the company’s strong recent reported margins. If that trend continues, it could reduce the durability of shareholder returns, constrain reinvestment capacity, and signal that current earnings strength is not yet firmly established.
Unstable Capital Structure History
The recent swing from negative equity in 2023 to a strong TTM position shows that financial stability has not been consistent. Although the balance sheet is currently conservative, this history highlights vulnerability to future losses or uneven development economics if revenue volatility returns.
Saniona AB News
SANION FAQ
What was Saniona AB’s price range in the past 12 months?
What is Saniona AB’s market cap?
When is Saniona AB’s upcoming earnings report date?
How were Saniona AB’s earnings last quarter?
Is Saniona AB overvalued?
Does Saniona AB pay dividends?
What is Saniona AB’s EPS estimate?
How many shares outstanding does Saniona AB have?
What happened to Saniona AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Saniona AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Saniona AB
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas Feldthus
- Employees
- 44
- Website
- www.saniona.com
- Address
- Murervangen 42, Glostrup, CD, 2600, DK
Saniona AB (SANION) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 6 | 7 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 6 | 0 | 6 |






